AllDocs -> cancers

N ew research from Canada suggests that a diet rich in fruits and vegetables may help prevent pancreatic cancer , a particularly deadly type of tumor, Reuters said. The findings, based on a comparison of 585 pancreatic cancer patients and about 4,779 adults without the disease, suggest that the risk of the cancer declines as fruit and veg- etable intake increases. Among cancers, pancreatic tumors have one of the most dismal survival rates, with less than 5 percent of patients still alive 5 years after diagnosis. The poor prognosis is in large part due to the fact that the disease is rarely caught early. Because of this, uncovering the modifiable risk factors for the disease is vital, according to Dr. Parviz Ghadirian of the University of Montreal, one of the authors of the new study. Using data from a large study of Canadians diagnosed with cancer between 1994 and 1997, Ghadirian ...

Consensus Conference Pancreatology 2001;1:416–422 Pancreatic Cancer in Hereditary Pancreatitis: Consensus Guidelines for Prevention, Screening and Treatment Charles D. Ulrich for the Consensus Committees of the European Registry of Hereditary Pancreatic Diseases, the Midwest Multi-Center Pancreatic Study Group and the International Association of Pancreatology University of Cincinnati College of Medicine, Cincinnati, Ohio, USA Charles D. Ulrich, II, MD, FACP, FACG Associate Professor of Medicine, Pathobiology and Molecular Medicine University of Cincinnati College of Medicine, 231 Albert B. Sabin Way MSB Room 6555, ML 0595, Cincinnati, OH 45267-0595 (USA) Tel. +1 513 558 5244, Fax +1 513 558 1744, E-Mail charles.ulrich@uc.edu ABC Fax + 41 61 306 12 34 E-Mail karger@karger.ch www.karger.com © 2001 S. Karger AG, Basel and IAP Accessible online ...

The sensitivity of BIA in the presence of pancreatic cancer In late December of 1992 a male pancreatic cancer patient (age 71, height 69 inches) was admitted to the hospice program of the University of Indiana. A nurse assigned to this patient took BIA measurements each day for the last 127 days of the patients life. The patient eventually died in early May of 1993. The graphs illustrated in this manuscript were created using the same equations found in the RJL Systems Cyprus program[1]. Note: fat free mass is the sum of extracellular mass and body cell mass. Total body water is the sum of extracellular water and intracellular water. TPN started Wt (kg) Days to hospice Patient admitted Male, (age 71) pancreatic cancer patient, last 127 days of life Fat mass (kg) Fat free mass (kg) Weight TPN stopped death 100 80 60 40 20 0 ...

©2005 MC1185-60 The Mayo Clinic SPORE in Pancreatic Cancer is designed to facilitate and promote research in pancreatic cancer that is highly likely to result in benefit to patients who currently have very little hope or treatment options. We are focused on discovery of novel mechanisms and pathways that will help understand causes and mechanisms of pancreatic cancer , which in turn will be translated into strategies for prevention, early detection, and treatment. Pancreatic Cancer facts: • In 2005, there will be 32,180 new patients with pancreatic cancer , and 31,800 deaths. • 1 year survival is 24% and 5-year survival is 4%. • Cigarette smoking, diabetes, and family history have been identified as risk factors. • Each year, Mayo Clinic is visited by approximately 450 pancreatic cancer patients. • Mayo ...

JOP. J Pancreas (Online) 2005; 6(2):122-127. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 6, No. 2 – March 2005. [ISSN 1590-8577] 122 EDITORIAL Duodenal Acidity May Increase the Risk of Pancreatic Cancer in the Course of Chronic Pancreatitis: An Etiopathogenetic Hypothesis Giorgio Talamini Gastroenterology and Endoscopy Service, University of Verona. Verona, Italy Summary Chronic pancreatitis patients have an increased risk of developing pancreatic cancer . The cause of this increase has yet to be fully explained but smoking and inflammation may play an important role. To these, we must now add a new potential risk factor, namely duodenal acidity. Patients with chronic pancreatitis very often present pancreatic exocrine insufficiency combined with a persistently low duodenal pH in the postprandial period. The duodenal mucosa in ...

pancreatic cancer Preoperative (Neoadjuvant) Therapy Douglas B. Evans University of Texas M. D. Anderson Cancer Center June 17, 2003 Initial surgery is the correct treatment for the 10% to 20% without extra- pancreatic disease In the 80% with occult extra- pancreatic disease surgery delays systemic therapy 20% Additional concerns: angiogenesis / immune suppression Delivery of Neoadjuvant Therapy Surgical Oncology Diagnostic Imaging Gastroenterology Cytopathology Gastrointestinal Medical Oncology Radiation Oncology Nutrition Support Rationale for preop therapy Multimodality therapy superior to surgery alone Delayed recovery ...

TNFerade TM , in Pancreatic Cancer : Preliminary Results of the Dose-Escalating Phase of a Major Randomized Study in Patients with Locally Advanced Pancreatic Cancer Nader Hanna 1 ,Theodore Chung 2 , J. Randolph Hecht 3 , Stephen Vogel 4 , Alexander Rosemurgy 5 , John Nemunaitis 6 , Milind Javle 7 ,Tony Reid 8 , Paul Kessler 9 , Mitchell Posner 10 , Kenneth Chang 11 , Neil Senzer 6 1 University of Kentucky, Lexington, KY; 2 Medical College of Virginia, Richmond,VA; 3 University of California at Los Angeles; 4 University of Florida, Gainesville, FL; 5 University of South Florida,Tampa, ...

A Novel Gene Transfer Therapy Against Pancreatic Cancer (TNFerade) Delivered by Endoscopic Ultrasound (EUS) and Percutaneous Guided Fine Needle Injection (FNI) Kenneth Chang, Nader Hanna, Stephen Swisher, Theodore Chung, J. Randolph Hecht, Stephen Vogel, Alexander Rosemurgy, John Nemunaitis, John Gibbs, Tony Reid, Jennifer Macko, Paul Kessler, Mitchell Posner, James Farrell, Shane Grundy, Harlan Pinto, Roy Soetikno, Irving Waxman, Neil Senzer A Novel Gene Transfer Therapy Against A Novel Gene Transfer Therapy Against Pancreatic Cancer ( Pancreatic Cancer ( TNFerade TNFerade ) Delivered by ) Delivered by Endoscopic Endoscopic Ultrasound (EUS) and Ultrasound (EUS) and Percutaneous Percutaneous Guided Fine Needle Injection (FNI) Guided Fine Needle Injection (FNI) Kenneth Chang, Kenneth ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2001;7(5):622-626 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright © 2001 by The WJG Press ISSN 1007-9327 • REVIEW • Recent advances in the surgical treatment of pancreatic cancer A Shankar and RCG Russell Department of Surgery, The Middlesex Hospital, Mortimer Street, London, W1N 8AA, UK Correspondence to: A Shankar, Department of Surgery, The Middlesex Hospital, Mortimer Street, London, W1N 8AA, UK Received 2001-05-15 Accepted 2001-06-15 Subject headings pancreatic neoplasms/surgery; pancreatic neoplasms/diagnosis Shankar A, Russell RCG. Recent advances in the surgical treatment of pancreatic cancer . World J Gastroenterol, 2001;7(5):622-626 INTRODUCTION Pancreatic cancer remains the fourth commonest ...

JOP. J Pancreas (Online) 2005; 6(1 Suppl.):60-67. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 6, No. 1 Supplement – January 2005. [ISSN 1590-8577] 60 AISP - 28th National Congress. Verona (Italy). October 28-30, 2004. Genetics of Pancreatic Cancer : Where Are We Now? Where Are We Going? Marco Del Chiaro, Ugo Boggi, Silvano Presciuttini, Laura Bertacca, Chiara Croce, Irene Mosca, Franco Mosca Division of General and Transplant Surgery, Regional Referral Center for Pancreatic Diseases Treatment, University of Pisa. Pisa, Italy Pancreatic adenocarcinoma represents about 90% of all pancreatic tumors [1]. In Italy, the incidence of ductal adenocarcinoma is about 7,000 new cases per year and the mortality rate is about 95% [2]. For this reason, pancreatic cancer is the fifth cause of death from cancer in Italy [3]. The only chance ...

Pharmacologic Therapies COLORECTAL & GI CANCERS a report by Gauri R Varadhachar y , MD and James L Abbr uzzese , MD , FACP Assistant Professor, and Chairman, Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center Pancreatic cancer is the fourth leading cause of cancer - related death and has the highest case fatality rate.In 2004, approximately 31,860 new cases will be diagnosed, and 31,270 of affected patients are expected to die from their disease.Patients usually present with advanced disease,and two-thirds of them either have locally advanced or metastatic disease. Presentation may depend on location of the primary, with more pain in patients with tumors involving the body and tail of the pancreas, and obstructive jaundice in patients ...

Pancreatic Cancer The National Cancer Institute ( http://www. cancer .gov/ ), lists pancreatic cancer as one of 13 common causes of cancer and provides the following information. To obtain a free copy of this document, go to www.masterdocs.com . Understanding Cancer Cancer begins in cells, the building blocks that make up tissues . Tissues make up the organs of the body. Normally, cells grow and divide to form new cells as the body needs them. When cells grow old, they die, and new cells take their place. Sometimes this orderly process goes wrong. New cells form when the body does not need them, and old cells do not die when they should. These extra cells can form a mass of tissue called a growth or tumor . Not all tumors are cancer . Tumors can be benign or malignant : Benign tumors are not cancer : • Benign tumors are rarely life-threatening. ...

JOP. J Pancreas (Online) 2005; 6(1):42-46. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 6, No. 1 – January 2005. [ISSN 1590-8577] 42 PANCREAS NEWS Some More News on the Metastatic Pathway in Pancreatic Cancer Generoso Uomo Department of Internal Medicine, Cardarelli Hospital. Naples, Italy Pancreatic cancer (PK) is a highly aggressive type of malignancy and the prognosis for this condition which typically presents at a late stage is extremely poor. Invasiveness is an early phenomenon, and extensive local/distant metastasis represents the rule in clinical practice. In this context, a comprehensive understanding of the metastatic pathway(s) seems to be basic for the improvement of the limited therapeutic weapons currently at our disposal. Very recently, some studies have addressed this subject, giving new and important information on the ...

CORTACTIN TYROSINE PHOSPHORYLATION ENHANCES LAMELLIPODIUM FORMATION IN PANCREATIC CANCER CELLS Anne E. Kruchten*, Eugene Krueger, Mark A. McNiven Mayo Clinic College of Medicine, Dept. of Biochemistry and Molecular Biology 200 1 st Street SW, Rochester, MN 55905 *kruchten.anne@mayo.edu BACKGROUND Cortactin was originally identified as a prominent substrate of c-Src (1) and is substantially overexpressed in several types of cancers (2). Cortactin is thought to mediate cytoskeletal reorganization and lamellipodial extension in response to EGF stimulation. Three tyrosines have been identified as c-Src targets (figure 1), but no definitive in vivo role for cortactin phosphorylation has been determined. Expression of a cortactin protein with mutations of its tyrosine residues results in inhibited motility in endothelial cells (3). Here we report the effect of cortactin ...

HUMAN STEM CELLS DERIVED FROM CORD BLOOD REDUCES THE SIZE OF PANCREATIC TUMOR IN SCID MICE. Jay P Sharma***, Saroj K. Basak ++ ***CELPROGEN INC., SAN PEDRO, CA 90731; ++ University of California (UCLA), Los Angeles, CA. Request for off prints should be addressed to: Jay P. Sharma; email: stemcells@celprogen.com Introduction: Pancreatic cancer has markedly increased incidence over the past several decades, and ranks as the fourth leading cause of cancer death in the United States. Despite the high mortality rate associated with pancreatic cancer , its etiology is poorly understood. This discrepancy reflects the current lack of effective treatment available for the pancreatic cancer patient and highlights the urgent need for novel therapeutic approaches in this area. Celprogen’s Stem Cell based therapy for pancreatic cancer utilizes Celprogen’s ...

ASX RELEASE 10 September, 2004 AustCancer Licenses Phase I/II Pancreatic Cancer Drug · Completed successful Phase I/II clinical pilot study · Strong response in metastasized pancreatic cancer patients · US Phase IIb/III pivotal trial to begin in 2005 Australian Cancer Technology ("AustCancer") (ASX:ACU) announced today that it had signed an agreement with the German company RESprotect GmbH, to acquire the North American licence to a developmental pancreatic cancer drug. The drug, RP101, has demonstrated promising results in a clinical Phase I/II pilot study. AustCancer has developed an accelerated clinical trial program for RP101 which would include application to the US FDA for Orphan Drug status. RP101 is targeted at preventing cells from developing a resistance to chemotherapy, one of the most challenging areas facing oncologists. RP101 would be used as a ...

JOP. J Pancreas (Online) 2004; 5(5):397-399. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 5, No. 5 – September 2004. [ISSN 1590-8577] 397 PANCREAS NEWS Pancreatic Cancer : The Effect of Specialization and New Medical Treatment Generoso Uomo, Raffaele Pezzilli Internal Medicine Department, 3rd Division, A. Cardarelli Hospital. Neaples, Italy. Department of Internal Medicine, Sant'Orsola-Malpighi Hospital. Bologna, Italy Within the past decade, many studies of patients having pancreatic cancer have shown a reduced post-operative morbidity and mortality rate as well as longer survival when treated in specialist regional Centres. A significant reduction in post-operative mortality rates in high- versus low-volume hospitals was observed both in the USA [1] and in Europe [2]. In-hospital mortality rates range from 14 to 28% in Centres with 1 to ...

Review 2002 © Ashley Publications Ltd ISSN 1354-3784 1 Ashley Publications www.ashley-pub.com 1. Introduction 2. Gemcitabine – the present standard 3. Novel agents and enzymes 4. Novel immunological strategies 5. Novel strategies for treatment 6. Expert opinion and outlook Monthly Focus: Oncologic Novel treatments and therapies in development for pancreatic cancer Walter H Günzburg 1 , Matthias Löhr 2 & Brian Salmons 3 1 Institute of Virology, University of Veterinary Sciences, Veterinärplatz 1, A-1210 Vienna, Austria; 2 Molecular Gastroenterology, Department of Medicine II, Medical Faculty Mannheim, University of Heidelberg, Theodor Kutzer Ufer, D-68135 Mannheim, Germany and 3 Austrianova, Veterinärplatz 1, A-1210 Vienna, Austria ...

Recent advances on Hepato-billary- pancreatic Cancer Aichi Cancer Center International Symposium III International Conference Hall Aichi Cancer Center Nagoya, Japan December 13-14, 1996 Page 2 1 Aichi Cancer Center International Symposium III Recent advances on Hepato-biliary- pancreatic Cancer Committee of the Aichi Cancer Center International Symposium Chairperson: Makoto Ogawa Shigeru Kawamoto Noboru Shimomura Morikuni Murakami Tsuyoshi Kito Takashi Hirai Suketami Tominaga Toshitada Takahashi Masao Seto Organizing committee of the Third Symposium Chairperson : Kazuhiko Ohhashi Yasuaki Arai Takeshi Morimoto Kenzo Yasui Junichi Sakamoto Masae Tatematsu Osamu Takagi Page 3 2 Friday, December 13, 1996 ...

doi:10.1016/j.ijrobp.2003.11.019 CLINICAL INVESTIGATION Pancreas INTENSITY-MODULATED RADIOTHERAPY (IMRT) AND CONCURRENT CAPECITABINE FOR PANCREATIC CANCER E DGAR B EN -J OSEF , M.D.,* A NTHONY F. S HIELDS , M.D., P H .D., † U LKA V AISHAMPAYAN , M.D., † V AINUTIS V AITKEVICIUS , M.D., † B ASIL F. E L -R AYES , M.D., † P ATRICK M C D ERMOTT , P H .D.,* J AY B URMEISTER , P H .D.,* T ODD B OSSENBERGER , R.T.T., C.M.D.,* AND P HILIP A. ...

JOP. J Pancreas (Online) 2003; 4(5):165-168. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 4, No. 5 – September 2003 165 The Race from Chronic Pancreatitis to Pancreatic Cancer Giulia Martina Cavestro 1 , Giuseppe Comparato 1 , Antonio Nouvenne 1 , Mario Sianesi 2 , Francesco Di Mario 1 1 Department of Clinical Science, Chair of Gastroenterology; 2 Department of Surgical Science, General Surgery and Organ Transplantation; University of Parma. Parma, Italy The latest data on pancreatic cancer epidemiology were published in 2002 by the American National Cancer Institute. It was confirmed as the 5 th leading cause of death from cancer , causing more than 24,000 deaths each year. The fact that nearly all patients die from ...

JOP. J Pancreas (Online) 2003; 4(4):163-164. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 4, No. 4 – July 2003 163 LETTER Helicobacter pylori and Pancreatic Cancer . A Working Hypothesis from Epidemiological Studies Stefan Wöhrer, Michael Hejna, Markus Raderer Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna. Vienna, Austria Dear Sir: We have read the informative article about Helicobacter pylori (HP) and pancreatic disease written by Manes et al . with great interest [1]. We were, however, slightly puzzled by the statement that no data on a potential association between Helicobacter pylori infection and pancreatic cancer are available. According to recent data, two articles and one letter about an association between the bacteria and pancreatic cancer have been published. In the ...

New and Emerging Technology Briefing Rubitecan resistant refractory pancreatic cancer July 2003 Horizon Scanning Review Early assessments of new or emerging technologies contain time-limited information and should be used with due caution. Not to be used for commercial purposes National Horizon Scanning Centre Page 2 National Horizon Scanning Centre RUBITECAN July 2003 1 Rubitecan for resistant or refractory pancreatic cancer Summary Rubitecan (Orathecin, RFS2000, 9-nitrocampothecin), is a DNA topoisomerase I inhibitor that is pre-registration for resistant or refractory pancreatic cancer . Phase III trials are yet to be published. Phase II trials suggest that rubitecan can lead to an increased survival in a proportion of patients treated. Developer ...

New and Emerging Technology Briefing G17DT for pancreatic , stomach and colorectal cancer January 2003 Horizon Scanning Review Early assessments of new or emerging technologies contain time-limited information and should be used with due caution. Not to be used for commercial purposes National Horizon Scanning Centre Page 2 National Horizon Scanning Centre G17DT Jnauary 2003 2 G17DT for pancreatic , stomach and colorectal cancer Summary G17DT is a vaccine that neutralises gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2004;10(15):2292-2294 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright © 2004 by The WJG Press ISSN 1007-9327 • BRIEF REPORTS • Effect of octreotide on human pancreatic cancer cells after transfected with somatostatin receptor type 2 gene Zheng-Ren Liu, Ren-Yi Qin, Gao-Song Wu, Qing Chang, Da-Yu Wang, Sheng-Quan Zou, Fa-Zu Qiu Zheng-Ren Liu, Ren-Yi Qin, Gao-Song Wu, Qing Chang, Da- Yu Wang, Sheng-Quan Zou, Fa-Zu Qiu, Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China Supported by the Natural Science Foundation of Hubei Province, No. 2000J068 Correspondence to: Professor Ren-Yi Qin, Department of General Surgery, Tongji ...

JOP. J Pancreas (Online) 2004; 5(4):289-303. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 5, No. 4 – July 2004. [ISSN 1590-8577] 289 ROUND TABLE Defining the Diagnostic Algorithm in Pancreatic Cancer John David Horwhat, Frank G Gress Division of Gastroenterology, Department of Medicine, Duke University Medical Center. Durham, North Carolina, USA Summary Most patients with pancreatic cancer present with a mass on radiologic studies, however, not every pancreatic mass is cancer . Since radiological studies alone are insufficient to establish the diagnosis of a pancreatic mass and patient management depends on a definitive diagnosis; confirmatory cytology or histology is usually required. As a minimally invasive procedure, EUS and EUS FNA avoid the risk of cutaneous or peritoneal contamination that may occur with CT or US- guided ...

JOP. J Pancreas (Online) 2004; 5(4):253-257. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 5, No. 4 – July 2004. [ISSN 1590-8577] 253 ROUND TABLE Pancreatic Cancer Imaging: Which Method? Erwin Santo Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center. Tel Aviv, Israel Summary Pancreatic cancer is the 10 th most common malignancy and the 4 th largest cancer killer in adults. Surgery offers the only chance of curing these patients. Complete surgical resection is associated with a 5-year survival rate of between 20 and 30%. The challenge is how to best select those patients for curative surgery. Early studies demonstrated excellent sensitivity of EUS in detecting pancreatic tumors in comparison to CT. Similarly, EUS showed an 85-94 % accuracy rate for T ...

JOP. J Pancreas (Online) 2004; 5(4):240-242. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 5, No. 4 – July 2004 240 PANCREAS NEWS Screening Tests for Pancreatic Cancer : Searching for the Early Symptoms or the Population at Risk Raffaele Pezzilli Department of Internal Medicine, Sant'Orsola-Malpighi Hospital. Bologna, Italy In the past four decades, the incidence of pancreatic cancer has increased steadily in most of the world and now this type of tumor ranks as the fifth or sixth most frequent cause of death due to cancer in many western countries [1]. For example, in 2000, worldwide figures for pancreatic cancer were projected at 216,400 new cases and 213,500 deaths [2]; the data coming from the United States in 2004, estimated that 31,860 patients would be diagnosed with pancreatic cancer and 31,270 would die of the disease ...

Tumori, 90: 192-195, 2004 Correspondence to: Ozkan Kanat, MD, Uludag University Faculty of Medicine Department of Medical Oncology, Gorukle 16059, Bursa, Turkey. Tel +90-224-4428400; fax +90-224-4428049; e-mail ozkanat@uludag.edu.tr Received July 7, 2003; accepted September 8, 2003. TREATMENT OF METASTATIC PANCREATIC CANCER WITH A COMBINATION OF GEMCITABINE AND 5-FLUOROURACIL: A SINGLE CENTER PHASE II STUDY Ozkan Kanat,Turkkan Evrensel, Ender Kurt, Mutlu Demiray, Guzin Gonullu, Murat Arslan, and Osman Manavoglu Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey Key words: chemotherapy, gemcitabine, 5-fluorouracil, pancreatic cancer . Aim : To determine the activity and toxicity of a combination of weekly gemcitabine and 5-fluorouracil bolus intravenously in patients with metastatic pancreatic cancer . Patients and methods : ...